Company
(location)

Partner
(location)

Amt.
(M)

Details

Date

TOTAL: $159.2M (Year to Date: $667.86M)

Biospecifics Technologies Corp. (Lynbrook, N.Y.)

Asahi Kasei Corp. (Tokyo)

$1

For the first commercial sale of Xiaflex to treat Dupuytren's contracture in Japan

9/22/15

Enumeral Biomedical Holdings Inc. (Cambridge, Mass.)

Merck Sharp & Dohme Corp. (part of Merck & Co. Inc.; Kenilworth, N.J.)

ND

Achieved its first milestone under the collaboration focused on immune-oncology research that employs Enumeral's Human Approach immune profiling technology with colorectal cancer patient tissues and identifies functional cellular responses

9/9/15

Nektar Therapeutics Inc. (San Francisco)

Astrazeneca plc (London)

$40

For the first commercial sale of Moventig (naloxegol) in Germany

9/2/15

Orexigen Therapeutics Inc. (San Diego)

Takeda Pharmaceutical Co. Ltd. (Osaka, Japan)

$15

Anniversary milestone payment for obesity drug Contrave (naltrexone HCl and bupropion HCl extended release)

9/24/15

Oryzon Genomics SA (Barcelona)

Roche AG (Basel, Switzerland)

$4

For the establishment of a recommended dose of ORY-1001 in a phase I trial in patients with relapsed or refractory acute leukemia

9/9/15

Pharmamar SA (Madrid)

Taiho Pharmaceutical Co. Ltd. (Tokyo) and Janssen Products

$99.2

For the marketing approval of Yondelis in Japan to treat patients with soft tissue sarcoma; Taiho paid $94.2M and Janssen paid $5M

9/29/15

Xencor Inc. (Monrovia, Calif.)

Janssen Biotech Inc. (Horsham, Pa.; unit of Johnson & Johnson)

ND

For initiating a phase II trial for CSL362 (JNJ-56033473)

9/25/15

Xenon Pharmaceuticals Inc. (Burnaby, British Columbia)

Genentech (unit of the Roche Group; Basel Switzerland)

ND

Xenon and Genentech have successfully discovered and identified a pain target by leveraging Xenon's Extreme Genetics platform based on the study of rare phenotypes of individuals who have either an inability to perceive pain or have non-precipitated spontaneous severe pain

9/22/15

Notes

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

This chart includes only biotech companies that develop therapeutics.

ND = Not disclosed.